Themis Medicare Limited (THEMISMED.BO)
INR 127.95
(6.14%)
INR 127.95
(6.14%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 435.23 Million INR | -23.51% |
| 2022 | 569.01 Million INR | -21.93% |
| 2021 | 728.8 Million INR | 104.13% |
| 2020 | 357.03 Million INR | 44.07% |
| 2019 | 247.81 Million INR | 330.71% |
| 2018 | -107.41 Million INR | -195.13% |
| 2017 | 112.91 Million INR | -29.25% |
| 2016 | 159.59 Million INR | -1.95% |
| 2015 | 162.77 Million INR | 162.02% |
| 2014 | 62.12 Million INR | 130.41% |
| 2013 | 26.96 Million INR | 142.68% |
| 2012 | -63.17 Million INR | 80.54% |
| 2011 | -324.7 Million INR | -384.81% |
| 2010 | 114.01 Million INR | -44.62% |
| 2009 | 205.85 Million INR | 281.29% |
| 2008 | -113.55 Million INR | -163.03% |
| 2007 | 180.15 Million INR | 69.02% |
| 2006 | 106.58 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 142.93 Million INR | -42.1% |
| 2024 Q1 | 246.84 Million INR | 271.56% |
| 2023 Q2 | 113.19 Million INR | -37.78% |
| 2023 Q3 | 73.68 Million INR | -34.91% |
| 2023 Q4 | 66.43 Million INR | -9.83% |
| 2023 FY | 435.23 Million INR | -23.51% |
| 2023 Q1 | 181.92 Million INR | 116.44% |
| 2022 Q4 | 84.05 Million INR | -36.86% |
| 2022 Q1 | 174.03 Million INR | 74.91% |
| 2022 FY | 569.01 Million INR | -21.93% |
| 2022 Q2 | 177.8 Million INR | 2.17% |
| 2022 Q3 | 133.11 Million INR | -25.13% |
| 2021 Q4 | 99.49 Million INR | -20.13% |
| 2021 Q1 | 311.98 Million INR | 287.42% |
| 2021 FY | 728.8 Million INR | 104.13% |
| 2021 Q2 | 192.75 Million INR | -38.22% |
| 2021 Q3 | 124.57 Million INR | -35.37% |
| 2020 Q4 | 80.52 Million INR | -31.54% |
| 2020 Q3 | 117.63 Million INR | 44.61% |
| 2020 FY | 357.03 Million INR | 44.07% |
| 2020 Q1 | 77.52 Million INR | 6.55% |
| 2020 Q2 | 81.34 Million INR | 4.92% |
| 2019 Q2 | 16.78 Million INR | -67.47% |
| 2019 Q4 | 72.76 Million INR | -31.8% |
| 2019 Q1 | 51.58 Million INR | 145.18% |
| 2019 FY | 247.81 Million INR | 330.71% |
| 2019 Q3 | 106.68 Million INR | 535.68% |
| 2018 Q3 | 1.07 Million INR | 136.88% |
| 2018 Q2 | -2.92 Million INR | -134.0% |
| 2018 Q1 | 8.59 Million INR | -81.87% |
| 2018 FY | -107.41 Million INR | -195.13% |
| 2018 Q4 | -114.16 Million INR | -10690.72% |
| 2017 Q4 | 47.42 Million INR | 86.41% |
| 2017 FY | 112.91 Million INR | -29.25% |
| 2017 Q2 | 70.17 Million INR | 0.0% |
| 2017 Q3 | 25.43 Million INR | -63.75% |
| 2016 Q3 | 63.67 Million INR | 197.32% |
| 2016 FY | 159.59 Million INR | -1.95% |
| 2016 Q2 | 21.41 Million INR | -70.83% |
| 2016 Q1 | 73.42 Million INR | 128.56% |
| 2016 Q4 | 4.34 Million INR | -93.17% |
| 2015 Q1 | 58.39 Million INR | 1092.1% |
| 2015 Q3 | 47.68 Million INR | -27.64% |
| 2015 Q4 | 32.12 Million INR | -32.63% |
| 2015 FY | 162.77 Million INR | 162.02% |
| 2015 Q2 | 65.89 Million INR | 12.85% |
| 2014 Q3 | 24 Million INR | 513.33% |
| 2014 FY | 62.12 Million INR | 130.41% |
| 2014 Q2 | -5.8 Million INR | 0.0% |
| 2014 Q4 | -5.88 Million INR | -124.52% |
| 2013 FY | 26.96 Million INR | 142.68% |
| 2012 Q1 | 608 Thousand INR | 0.0% |
| 2012 FY | -63.17 Million INR | 80.54% |
| 2012 Q3 | -40.14 Million INR | -3045.63% |
| 2012 Q2 | 1.36 Million INR | 124.18% |
| 2012 Q4 | -9.54 Million INR | 76.22% |
| 2011 FY | -324.7 Million INR | -384.81% |
| 2010 FY | 114.01 Million INR | -44.62% |
| 2009 FY | 205.85 Million INR | 281.29% |
| 2008 FY | -113.55 Million INR | -163.03% |
| 2007 FY | 180.15 Million INR | 69.02% |
| 2006 FY | 106.58 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 92.932% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 98.628% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 90.757% |
| Granules India Limited | 4.05 Billion INR | 89.262% |
| Indoco Remedies Limited | 984.6 Million INR | 55.795% |
| Achyut Healthcare Limited | 5.73 Million INR | -7493.126% |
| Ajanta Pharma Limited | 8.16 Billion INR | 94.667% |
| Alkem Laboratories Limited | 17.95 Billion INR | 97.576% |
| Alpa Laboratories Limited | 167.76 Million INR | -159.433% |
| Brooks Laboratories Limited | -195.91 Million INR | 322.152% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 73.052% |
| Bajaj HealthCare Limited | -837.93 Million INR | 151.942% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 42.318% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 99.218% |
| Eris Lifesciences Limited | 3.91 Billion INR | 88.897% |
| FDC Limited | 3.05 Billion INR | 85.74% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 102.898% |
| Gufic Biosciences Limited | 861.35 Million INR | 49.471% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 89.661% |
| Ipca Laboratories Limited | 5.47 Billion INR | 92.048% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -93.758% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 320.615% |
| Lasa Supergenerics Limited | -217.3 Million INR | 300.288% |
| Laurus Labs Limited | 1.6 Billion INR | 72.891% |
| Lupin Limited | 19.14 Billion INR | 97.727% |
| Mankind Pharma Limited | 19.12 Billion INR | 97.725% |
| Medicamen Biotech Limited | 109.31 Million INR | -298.169% |
| Medico Remedies Limited | 82.9 Million INR | -424.959% |
| Megasoft Limited | -127.46 Million INR | 441.454% |
| NATCO Pharma Limited | 13.88 Billion INR | 96.865% |
| Piramal Pharma Limited | 178.2 Million INR | -144.241% |
| RPG Life Sciences Limited | 876.6 Million INR | 50.349% |
| Sigachi Industries Limited | 571.8 Million INR | 23.883% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 99.546% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 85.506% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -71.934% |
| Unichem Laboratories Limited | -704.74 Million INR | 161.758% |
| Wanbury Limited | 559.56 Million INR | 22.218% |
| Windlas Biotech Limited | 581.87 Million INR | 25.2% |
| ZIM Laboratories Limited | 172.46 Million INR | -152.365% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 98.872% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 111.24% |
| Divi's Laboratories Limited | 16 Billion INR | 97.28% |
| Hester Biosciences Limited | 188.89 Million INR | -130.419% |
| Procter & Gamble Health Limited | 2 Billion INR | 78.344% |
| Amrutanjan Health Care Limited | 449.72 Million INR | 3.222% |
| Bal Pharma Limited | 73.92 Million INR | -488.78% |
| Strides Pharma Science Limited | -706.14 Million INR | 161.636% |
| Venus Remedies Limited | 284.9 Million INR | -52.764% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 79.934% |
| Nectar Lifesciences Limited | 49.95 Million INR | -771.347% |
| Shilpa Medicare Limited | 318.74 Million INR | -36.549% |
| Aarti Drugs Limited | 1.71 Billion INR | 74.61% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 67.623% |
| Suven Life Sciences Limited | -1.05 Billion INR | 141.421% |
| Ind-Swift Limited | 142.31 Million INR | -205.832% |
| Valiant Laboratories Limited | 3.19 Million INR | -13518.21% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 92.124% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 107.671% |
| Hikal Limited | 696.02 Million INR | 37.468% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 97.372% |
| Sequent Scientific Limited | -358.69 Million INR | 221.341% |
| Novartis India Limited | 851.9 Million INR | 48.91% |
| Wockhardt Limited | -4.63 Billion INR | 109.4% |
| Jubilant Pharmova Limited | 771 Million INR | 43.549% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -6037.028% |
| Neuland Laboratories Limited | 3 Billion INR | 85.496% |
| Morepen Laboratories Limited | 961.59 Million INR | 54.738% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -198.08% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 579.776% |